Overview

A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.

Status:
Active, not recruiting

Trial end date:
2025-10-10

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Antineoplastic Agents
Atezolizumab
Paclitaxel